Vasopressin

Summary

Vasopressin (CHEMBL373742) is an approved protein cardiovascular drug targeting AVPR1A, AVPR1B, and AVPR2; indicated across 20 conditions including diabetes insipidus and toxic shock syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Targets: 4 (AVPR1A, AVPR1B, AVPR2…)
• Indications: 20 conditions
• Clinical trials: 85
• Chemistry: 1084.2 Da · C46H65N15O12S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL373742
Name	Vasopressin
Type	Protein
Max phase	4
FDA approved	yes
PubChem CID	644077
ChEBI	CHEBI:34543
Molecular formula	C46H65N15O12S2
Molecular weight	1084.2
InChIKey	KBZOIRJILGZLEJ-LGYYRGKSSA-N

SMILES: C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N

IUPAC name: (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide

ChEBI definition: The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.

Pharmacological roles (ChEBI): cardiovascular drug, hematologic agent, mitogen.

Also known as: Arginine vasopressin, Argipressin or lypressin, Beta-hypophamine, Inyectable de vasopresina, Leiormone, Solute injectable de vasopressine, Vasopressin, Vasopressin component of hbn-1, Vasopressin injection, unspecified, Vasostrict, Vasophysin

Parent form; salt/anhydrous children: CHEMBL2360839

Patent coverage: 2,642 distinct patent families (7,202 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 6,960 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
AVPR1A	V1A receptor	Full agonist	9.3	4.6%	P37288
AVPR1B	V1B receptor	Full agonist	9.5	0.4%	P47901
AVPR2	V2 receptor	Full agonist	9.1	0%	P30518
OXTR	OT receptor	Partial agonist	9.3	0.1%	P30559

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Vasopressin V2 receptor, Vasopressin V1a receptor, Vasopressin V1b receptor, Oxytocin receptor, Vasopressin V1 receptor, Vasopressin V2 receptor, Vasopressin V1b receptor, Vasopressin V1a receptor, Vasopressin V2 receptor, Vasopressin V2 receptor, Oxytocin receptor.

Bioactivity

ChEMBL activities: 61 potent at pChembl ≥ 5 of 61 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
AVPR2	10.3	EC50	0.05	nM	CHEMBL_ACT_15001078
AVPR2	10.3	EC50	0.05	nM	CHEMBL_ACT_6324469
AVPR2	10.3	EC50	0.05	nM	CHEMBL_ACT_6336614
AVPR2	10.28	EC50	0.05	nM	CHEMBL_ACT_1683273
P30560	10.2	EC50	0.06	nM	CHEMBL_ACT_6324607
P30560	10.15	EC50	0.07	nM	CHEMBL_ACT_6323637
OXTR	10	EC50	0.1	nM	CHEMBL_ACT_19206190
AVPR1A	9.63	EC50	0.23	nM	CHEMBL_ACT_6323707
AVPR1A	9.62	EC50	0.24	nM	CHEMBL_ACT_15001144
AVPR1A	9.62	EC50	0.24	nM	CHEMBL_ACT_6336476
AVPR1A	9.59	Ki	0.26	nM	CHEMBL_ACT_1926661
P48974	9.54	Ki	0.29	nM	CHEMBL_ACT_1818251
AVPR1A	9.46	Ki	0.35	nM	CHEMBL_ACT_1926664
Q00788	9.35	Ki	0.45	nM	CHEMBL_ACT_1818252
AVPR1B	9.31	Ki	0.49	nM	CHEMBL_ACT_12107284
AVPR1A	9.25	Ki	0.56	nM	CHEMBL_ACT_1940305
AVPR1A	9.19	EC50	0.64	nM	CHEMBL_ACT_25663350
P30560	9.19	Kd	0.65	nM	CHEMBL_ACT_330257
P30560	9.19	Kd	0.65	nM	CHEMBL_ACT_774810
P30560	9.19	Kd	0.64	nM	CHEMBL_ACT_809325
P30560	9.19	Kd	0.65	nM	CHEMBL_ACT_809326
AVPR1B	9.17	Ki	0.68	nM	CHEMBL_ACT_6165325
AVPR1A	9.15	Ki	0.7	nM	CHEMBL_ACT_12107297
AVPR1A	8.96	Ki	1.1	nM	CHEMBL_ACT_6165324
AVPR1A	8.95	Ki	1.13	nM	CHEMBL_ACT_1940289
P70536	8.93	Ki	1.17	nM	CHEMBL_ACT_1818255
AVPR2	8.92	Ki	1.2	nM	CHEMBL_ACT_6165326
AVPR1A	8.89	Ki	1.3	nM	CHEMBL_ACT_1940307
AVPR2	8.87	Ki	1.36	nM	CHEMBL_ACT_12108220
AVPR1A	8.87	Ki	1.35	nM	CHEMBL_ACT_1926665
AVPR2	8.83	Ki	1.48	nM	CHEMBL_ACT_12107241
Q00788	8.82	Kd	1.5	nM	CHEMBL_ACT_330258
P48044	8.82	Kd	1.5	nM	CHEMBL_ACT_774809
P30560	8.81	Ki	1.54	nM	CHEMBL_ACT_1818254
AVPR1A	8.81	Ki	1.53	nM	CHEMBL_ACT_1926666
OXTR	8.78	Ki	1.65	nM	CHEMBL_ACT_12107268
OXTR	8.77	Ki	1.7	nM	CHEMBL_ACT_6165327
AVPR1A	8.7	Ki	2	nM	CHEMBL_ACT_18285548
AVPR1B	8.7	Ki	2	nM	CHEMBL_ACT_18285554
OXTR	8.7	Ki	2	nM	CHEMBL_ACT_19206181
AVPR1B	8.7	EC50	2	nM	CHEMBL_ACT_6165309
AVPR1B	8.48	EC50	3.33	nM	CHEMBL_ACT_25663355
P32307	8.48	IC50	3.3	nM	CHEMBL_ACT_75378
AVPR1A	8.4	Ki	3.95	nM	CHEMBL_ACT_1926667
AVPR1B	8.37	EC50	4.3	nM	CHEMBL_ACT_15001211
AVPR1B	8.37	EC50	4.27	nM	CHEMBL_ACT_6324400
AVPR1B	8.37	EC50	4.3	nM	CHEMBL_ACT_6336545
OXTR	8.22	Ki	6	nM	CHEMBL_ACT_18285566
OXTR	8.08	EC50	8.3	nM	CHEMBL_ACT_6165315
P30560	8	IC50	10	nM	CHEMBL_ACT_75377
AVPR1B	7.96	EC50	11	nM	CHEMBL_ACT_24981440
OXTR	7.92	Ki	12	nM	CHEMBL_ACT_5119974
OXTR	7.82	EC50	15.14	nM	CHEMBL_ACT_6324538
OXTR	7.82	EC50	15	nM	CHEMBL_ACT_6336683
OXTR	7.66	EC50	22	nM	CHEMBL_ACT_15001066
AVPR2	7.5	Ki	32	nM	CHEMBL_ACT_18285560
AVPR1A	7.5	EC50	32	nM	CHEMBL_ACT_24981431
AVPR2	7.4	EC50	40	nM	CHEMBL_ACT_27021596
OXTR	7.39	EC50	41	nM	CHEMBL_ACT_5119983
AVPR2	6.62	IC50	242	nM	CHEMBL_ACT_12674598
AVPR1B	5.27	EC50	5400	nM	CHEMBL_ACT_27021599

Target pathways

Aggregated over 4 target gene(s): AVPR1A, AVPR1B, AVPR2, OXTR.

Top Reactome pathways

8 total, by targets touching each:

Pathway	Targets	Genes
Vasopressin-like receptors	4	AVPR1A, AVPR1B, AVPR2, OXTR
G alpha (q) signalling events	3	AVPR1A, AVPR1B, OXTR
Defective AVP does not bind AVPR1A,B and causes neurohypophyseal diabetes insipidus (NDI)	2	AVPR1A, AVPR1B
G alpha (s) signalling events	1	AVPR2
Vasopressin regulates renal water homeostasis via Aquaporins	1	AVPR2
Cargo recognition for clathrin-mediated endocytosis	1	AVPR2
Clathrin-mediated endocytosis	1	AVPR2
Defective AVP does not bind AVPR2 and causes neurohypophyseal diabetes insipidus (NDI)	1	AVPR2

Dominant GO biological processes

GO term	Targets
regulation of systemic arterial blood pressure by vasopressin	4
G protein-coupled receptor signaling pathway	4
cellular response to hormone stimulus	4
positive regulation of vasoconstriction	4
signal transduction	4
positive regulation of blood pressure	3
positive regulation of systemic arterial blood pressure	2
positive regulation of cytosolic calcium ion concentration	2
positive regulation of cell population proliferation	2
telencephalon development	2
transport across blood-brain barrier	2
regulation of blood pressure	2
maternal aggressive behavior	1
generation of precursor metabolites and energy	1
negative regulation of female receptivity	1

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
diabetes insipidus	4	MONDO:0004782	MONDO:0004782

12 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
toxic shock syndrome	3	MONDO:0001881	EFO:0006834
cardiac arrest	3	MONDO:0000745	EFO:0009492
benign muscle neoplasm	3	MONDO:0003061	MONDO:0003061
heart disorder	3	MONDO:0005267	EFO:0003777
syndromic disease	3	MONDO:0002254	MONDO:0002254
autism spectrum disorder	2	MONDO:0005258	EFO:0003756
autism	2	MONDO:0005260	EFO:0003758
acute lung injury	2	MONDO:0015796	EFO:0004610
congenital heart disease	2	MONDO:0005453	EFO:0005207
leiomyoma	2	MONDO:0001572	MONDO:0001572
major depressive disorder	2	MONDO:0002009	MONDO:0002009
pulmonary hypertension	2	MONDO:0005149	MONDO:0005149

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 85.

Phase distribution

Phase	Trials
Not specified	27
PHASE4	18
PHASE3	11
PHASE2	11
PHASE2/PHASE3	8
EARLY_PHASE1	5
PHASE1	4
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02118467	PHASE4	RECRUITING	Vasoactive Drugs in Intensive Care Unit
NCT06217562	PHASE4	ACTIVE_NOT_RECRUITING	Vasopressin for Septic Shock Pragmatic Trial
NCT06934798	PHASE4	RECRUITING	Inotropic Effects of Vasopressin Versus Noradrenaline In Patients With Vasoplegic Syndrome After Cardiac Surgery
NCT00127907	PHASE4	COMPLETED	Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest
NCT00799292	PHASE4	COMPLETED	Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial
NCT01393704	PHASE4	COMPLETED	Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial
NCT01700478	PHASE4	COMPLETED	Study of the Use of Misoprostol to Decrease Bleeding During a Myomectomy
NCT02454348	PHASE4	WITHDRAWN	NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock
NCT04602767	PHASE4	UNKNOWN	Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery
NCT04935814	PHASE4	COMPLETED	Cardiac Output Response to Vasopressin Infusion In Abdominal Surgery Patients Under Mechanical Ventilation
NCT05193370	PHASE4	WITHDRAWN	Angiotensin II vs. Vasopressin in Septic Shock
NCT05293041	PHASE4	COMPLETED	Argipressin’s Influence on Blood Loss During Hepatic Resection
NCT05439460	PHASE4	COMPLETED	Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension
NCT05506319	PHASE4	COMPLETED	Hypotension in the Weaning From Vasopressor Drugs
NCT05806307	PHASE4	UNKNOWN	Methods Decreasing Bleeding in Open Myomectomy
NCT05886192	PHASE4	UNKNOWN	The Construction and Application of Therapeutic System of Intelligent Decision-Oriented Hemodynamic Organized Therapy for Shock Patients
NCT06290596	PHASE4	UNKNOWN	Vasopressin Versus Tranexamic Acid for Control of Blood Loss Related to Abdominal Hysterectomy
NCT06419075	PHASE4	WITHDRAWN	Tranexamic Acid in Vaginal Reconstructive Surgery
NCT05568160	PHASE3	ACTIVE_NOT_RECRUITING	Evaluation of the Superiority of VAsopressin Versus NOradrenaline in the Management of Patients at Risk of Kidney Failure Undergoing Cardiac Surgery With Extracorporeal Circulation
NCT06344442	PHASE3	RECRUITING	Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)
NCT06464510	PHASE3	RECRUITING	Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis
NCT07052084	PHASE3	NOT_YET_RECRUITING	Systematic Adjunction of Vasopressine in Septic Shock
NCT07063680	PHASE3	RECRUITING	Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock
NCT00269685	PHASE2/PHASE3	COMPLETED	Comparison of Vasopressin and Other Pressors in Septic Shock
NCT00358579	PHASE3	COMPLETED	Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest
NCT00379522	PHASE2/PHASE3	COMPLETED	Vasopressin in Traumatic Hemorrhagic Shock Study
NCT00729794	PHASE3	COMPLETED	Vasopressin, Epinephrine, and Steroids for Cardiac Arrest
NCT00995839	PHASE2/PHASE3	COMPLETED	Terlipressin in Septic Shock: Effects on Microcirculation
NCT01505231	PHASE3	UNKNOWN	Vasopressin Versus Norepinephrine for the Management of Shock After Cardiac Surgery
NCT01718613	PHASE3	COMPLETED	Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients
NCT01861015	PHASE3	COMPLETED	Vasopressin Versus Epinephrine in Myomectomy
NCT02975999	PHASE2/PHASE3	COMPLETED	Use of Vasopressin Following the Fontan Operation
NCT03088345	PHASE2/PHASE3	COMPLETED	Early Use of Vasopressin in Post-Fontan Management
NCT03483753	PHASE2/PHASE3	WITHDRAWN	Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery
NCT03640949	PHASE2/PHASE3	COMPLETED	Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest
NCT03930069	PHASE2/PHASE3	COMPLETED	Vasopressin Injection Versus Misoprostol During Hysteroscopic Myomectomy In Reducing Blood Loss And Operation Time.
NCT04501861	PHASE3	COMPLETED	Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients:
NCT03446456	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Vasopressin and Pain Perception in the Brain
NCT05958342	PHASE2	RECRUITING	CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
NCT06547892	PHASE2	RECRUITING	Use of Vasopressin in Patients at High Risk of Acute Kidney Injury Admitted to the ICU
NCT07614438	PHASE2	NOT_YET_RECRUITING	Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery, a Randomized Open Label Trial
NCT00032747	PHASE2	COMPLETED	Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).
NCT00481572	PHASE2	COMPLETED	Continuous Infusion of Terlipressin in Septic Shock
NCT00624650	PHASE2	COMPLETED	Hemodynamics and Extravascular Lung Water in Acute Lung Injury
NCT01370096	PHASE2	TERMINATED	Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension
NCT01606384	PHASE2	COMPLETED	Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder
NCT01611935	PHASE2	COMPLETED	AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock
NCT01962870	PHASE2	COMPLETED	The Role of Vasopressin in the Social Deficits of Autism
NCT07446933	PHASE2	COMPLETED	Vasopressin vs. Uterine Artery Clamping for Laparoscopic Cesarean Scar Niche Repair
NCT05738148	PHASE1	ACTIVE_NOT_RECRUITING	Vasopressin vs. Epinephrine During Neonatal Cardiopulmonary Resuscitation
NCT00628550	PHASE1	COMPLETED	Trial of Vasopressin and Epinephrine to Epinephrine Only for In-Hospital Pediatric Cardiopulmonary Resuscitation
NCT01093768	PHASE1	COMPLETED	Brain Imaging Study of Adults With Autism Spectrum Disorders
NCT01327027	PHASE1	COMPLETED	Vasopressin Effects on Human Social Communication
NCT00420407	EARLY_PHASE1	TERMINATED	Low Dose Vasopressin in Traumatic Shock
NCT01680718	EARLY_PHASE1	COMPLETED	Neuropeptides and Social Behavior
NCT02394054	EARLY_PHASE1	COMPLETED	Vasopressin and the Social Brain
NCT02993640	EARLY_PHASE1	COMPLETED	Optimization of Hepatic Hemodynamics During Liver Surgery
NCT04463394	EARLY_PHASE1	COMPLETED	The Hemodynamic Effects of Vasopressin in Patients With Fontan Physiology
NCT04053478	Not specified	RECRUITING	Effects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study
NCT06234592	Not specified	RECRUITING	The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock
NCT06422975	Not specified	RECRUITING	Registry of Patients in Shock Treated With Vasopressin
NCT00795366	Not specified	COMPLETED	Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
NCT00816751	Not specified	COMPLETED	Paracervical Versus Intracervical Lidocaine
NCT00886262	Not specified	COMPLETED	Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant
NCT01296269	Not specified	UNKNOWN	Effects of Intranasal Oxytocin and Vasopressin on Social Behavior
NCT01318278	Not specified	COMPLETED	Study of Dopamine Versus Vasopressin for Treatment of Low Blood Pressure in Low Birth Weight Infants
NCT01493102	Not specified	TERMINATED	Discontinuation Order of Vasopressors in Septic Shock
NCT02053675	Not specified	COMPLETED	Hemodynamic Effects of Vasopressin in Early Septic Shock Stage
NCT02223429	Not specified	COMPLETED	Neurobiological Bases of Paternal Nurturance
NCT02526914	Not specified	UNKNOWN	Effects of Intranasal Oxytocin and Vasopressin on Social Behavior and Decision Making
NCT02726620	Not specified	COMPLETED	Decision Support for Intraoperative Low Blood Pressure
NCT03590873	Not specified	UNKNOWN	The Effect of Restrictive Fluid and Vasopressin During Surgery of Burn Patients
NCT03725553	Not specified	COMPLETED	Intra-myometrial Vasopressin During Cesarean Section in Placenta Previa
NCT03880045	Not specified	UNKNOWN	Topical Tranexamic Acid Plus Perivascular Vasopressin at the Time of Abdominal Myomectomy
NCT04214145	Not specified	COMPLETED	The Effect of Vasopressors on Cerebral Oxygentaion During Off Pump CABG
NCT04302584	Not specified	COMPLETED	Norepinephrine / Vasopressin Combination for Resuscitation in Septic Shock
NCT04372836	Not specified	UNKNOWN	Vasopressin Injection Technique to Preserve Ovarian Reserve in Surgery for Unilateral Ovarian Endometriomas
NCT04493554	Not specified	COMPLETED	The Effects of Vasopressin on Attention Control
NCT04715737	Not specified	COMPLETED	Differential Effects of Vasopressin and Oxytocin on Attention Control
NCT04874246	Not specified	COMPLETED	Comparison of Concentration of Vasopressin During Robot-assisted Laparoscopic Myomectomy
NCT04890470	Not specified	COMPLETED	Effects of Oxytocin and Vasopressin on Moral Decision Making
NCT05315557	Not specified	UNKNOWN	Efficacy and Safety of Vasopressin Versus Terlipressin as a Second Vasopressor in Critically Ill Cirrhotics With Septic Shock- the VITEL-C Trial
NCT06329037	Not specified	UNKNOWN	The Effects of Oral Vasopressin on Attention Control: An Eye-tracking Study
NCT06329063	Not specified	UNKNOWN	Oral Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study
NCT06426407	Not specified	TERMINATED	Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

143 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
DESMOPRESSIN	ChEMBL + PubChem	Phase 4 (approved)	AVPR1A, AVPR1B, AVPR2, OXTR
OXYTOCIN	ChEMBL + PubChem	Phase 4 (approved)	AVPR1A, AVPR1B, AVPR2, OXTR
ATOSIBAN	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR1B, AVPR2, OXTR
CARBETOCIN	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR1B, AVPR2, OXTR
MOZAVAPTAN	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR1B, AVPR2, OXTR
NELIVAPTAN	ChEMBL	Phase 2	AVPR1A, AVPR1B, AVPR2, OXTR
ORNIPRESSIN	ChEMBL	Phase 2	AVPR1A, AVPR1B, AVPR2, OXTR
PECAVAPTAN	ChEMBL	Phase 2	AVPR1A, AVPR1B, AVPR2, OXTR
SELEPRESSIN	ChEMBL	Phase 2	AVPR1A, AVPR1B, AVPR2, OXTR
LIXIVAPTAN	ChEMBL	Phase 3	AVPR1A, AVPR2, OXTR
Belzutifan	PubChem	Approved	AVPR1A, AVPR2, OXTR
PIMOZIDE	ChEMBL + PubChem	Phase 4 (approved)	AVPR1A, AVPR2
RIFAMPIN	ChEMBL + PubChem	Phase 4 (approved)	AVPR1A, AVPR2
TEGASEROD	ChEMBL + PubChem	Phase 4 (approved)	AVPR1A, AVPR2
BALSALAZIDE	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
BOSUTINIB	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
CONIVAPTAN	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
NITAZOXANIDE	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
PYRVINIUM	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
RIFAXIMIN	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
TOLVAPTAN	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
BALOVAPTAN	ChEMBL	Phase 3	AVPR1A, AVPR2
NOLASIBAN	ChEMBL	Phase 3	AVPR1A, OXTR
OTILONIUM BROMIDE	ChEMBL	Phase 3	AVPR1A, AVPR2
RETOSIBAN	ChEMBL	Phase 3	AVPR2, OXTR
SEMAXANIB	ChEMBL	Phase 3	AVPR1A, OXTR
BENZETHONIUM	ChEMBL	Phase 2	AVPR1A, AVPR2
DOMIPHEN	ChEMBL	Phase 2	AVPR1A, AVPR2
EPELSIBAN	ChEMBL	Phase 2	AVPR2, OXTR
RELCOVAPTAN	ChEMBL	Phase 2	AVPR1A, AVPR2
Abiraterone	PubChem	Approved	AVPR1A, AVPR2
acetylcysteine	PubChem	Approved	AVPR1A, AVPR2
Aclidinium Bromide	PubChem	Approved	AVPR1A, AVPR2
Acyclovir	PubChem	Approved	AVPR1A, AVPR2
Afatinib	PubChem	Approved	AVPR1A, AVPR2
Allopurinol	PubChem	Approved	AVPR1A, AVPR2
Almotriptan	PubChem	Approved	AVPR1A, AVPR2
Alogliptin	PubChem	Approved	AVPR1A, AVPR2
aminolevulinic acid	PubChem	Approved	AVPR1A, AVPR2
Anagrelide	PubChem	Approved	AVPR1A, AVPR2
Apixaban	PubChem	Approved	AVPR1A, AVPR2
Aprepitant	PubChem	Approved	AVPR1A, AVPR2
Bosentan	PubChem	Approved	AVPR1A, AVPR2
Clofarabine	PubChem	Approved	AVPR1A, AVPR2
Clozapine	PubChem	Approved	AVPR1A, AVPR2
Crizotinib	PubChem	Approved	AVPR1A, AVPR2
Dacarbazine	PubChem	Approved	AVPR1A, AVPR2
Desloratadine	PubChem	Approved	AVPR1A, AVPR2
Desoxycorticosterone Pivalate	PubChem	Approved	AVPR1A, AVPR2
Didanosine	PubChem	Approved	AVPR1A, AVPR2
Dihydroergotamine	PubChem	Approved	AVPR1A, AVPR2
Erythromycin	PubChem	Approved	AVPR1A, AVPR2
Ethambutol	PubChem	Approved	AVPR1A, AVPR2
Fidaxomicin	PubChem	Approved	AVPR1A, AVPR2
Fulvestrant	PubChem	Approved	AVPR1A, AVPR2
Ganciclovir	PubChem	Approved	AVPR1A, AVPR2
Gefitinib	PubChem	Approved	AVPR1A, AVPR2
Glycopyrrolate	PubChem	Approved	AVPR1A, AVPR2
Leucovorin	PubChem	Approved	AVPR1A, AVPR2
Linagliptin	PubChem	Approved	AVPR1A, AVPR2
Methotrexate	PubChem	Approved	AVPR1A, AVPR2
Olanzapine	PubChem	Approved	AVPR1A, AVPR2
Olmesartan Medoxomil	PubChem	Approved	AVPR1A, AVPR2
Pramipexole	PubChem	Approved	AVPR1A, AVPR2
Propoxyphene	PubChem	Approved	AVPR1A, AVPR2
Pyrazinamide	PubChem	Approved	AVPR1A, AVPR2
Rufinamide	PubChem	Approved	AVPR1A, AVPR2
saxagliptin	PubChem	Approved	AVPR1A, AVPR2
Sildenafil	PubChem	Approved	AVPR1A, AVPR2
Tadalafil	PubChem	Approved	AVPR1A, AVPR2
Tafamidis	PubChem	Approved	AVPR1A, AVPR2
Tamsulosin	PubChem	Approved	AVPR1A, AVPR2
Tiotropium Bromide Monohydrate	PubChem	Approved	AVPR1A, AVPR2
Valacyclovir	PubChem	Approved	AVPR1A, AVPR2
Valganciclovir	PubChem	Approved	AVPR1A, AVPR2
CINACALCET	ChEMBL + PubChem	Phase 4 (approved)	AVPR2
AMIODARONE	ChEMBL	Phase 4 (approved)	AVPR2
AMOXAPINE	ChEMBL	Phase 4 (approved)	AVPR2
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	AVPR1A
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	AVPR2
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	AVPR1A
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	AVPR1A
EPALRESTAT	ChEMBL	Phase 4 (approved)	AVPR1A
IDEBENONE	ChEMBL	Phase 4 (approved)	AVPR2
INDOCYANINE GREEN ACID FORM	ChEMBL	Phase 4 (approved)	AVPR1A
IPRINDOLE	ChEMBL	Phase 4 (approved)	AVPR2
ITRACONAZOLE	ChEMBL	Phase 4 (approved)	AVPR2
LASOFOXIFENE	ChEMBL	Phase 4 (approved)	AVPR2
MEFLOQUINE	ChEMBL	Phase 4 (approved)	AVPR2
NEBIVOLOL	ChEMBL	Phase 4 (approved)	AVPR2
NERATINIB	ChEMBL	Phase 4 (approved)	AVPR2
NIMESULIDE	ChEMBL	Phase 4 (approved)	AVPR2
PONATINIB	ChEMBL	Phase 4 (approved)	AVPR1A
RIMONABANT	ChEMBL	Phase 4 (approved)	AVPR1A
RITONAVIR	ChEMBL	Phase 4 (approved)	AVPR1A
SAQUINAVIR	ChEMBL	Phase 4 (approved)	AVPR1A
SERTINDOLE	ChEMBL	Phase 4 (approved)	AVPR2
SERTRALINE	ChEMBL	Phase 4 (approved)	AVPR2